All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
ASCO 2019 | What is the role of geriatric assessment in newly diagnosed multiple myeloma?
Featured:
Ashley Elizabeth RoskoAt the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Ashley Elizabeth Rosko, Ohio State University Wexner Medical Center, discusses how geriatric assessment should be implemented in treatment decisions in newly diagnosed multiple myeloma. Dr. Rosko explains that a geriatric assessment is a multi-dimensional approach to older adults, where geriatric domains such as physical function, nutritional, polypharmacy, psychosocial evaluation, cognitive evaluation, and geriatric syndromes are assessed. Dr. Rosko emphasizes that this is relevant for older adults because geriatric syndromes in multiple myeloma impact cancer care delivery.
What is the role of geriatric assessment in newly diagnosed multiple myeloma?
Your opinion matters
HCPs, which of the following best characterizes your perception of belantamab mafodotin in combination (BVd, BPd) for the treatment of relapsed/refractory multiple myeloma?